Jefferies Financial Group Reaffirms Buy Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Financial Group in a note issued to investors on Friday, Digital Look reports. They presently have a GBX 2,025 target price on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 27.36% from the stock’s current price.

A number of other equities analysts have also commented on HIK. Citigroup boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Finally, Berenberg Bank increased their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a report on Tuesday, August 11th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of GBX 2,085.83.

Hikma Pharmaceuticals Trading Down 2.2%

Shares of LON:HIK traded down GBX 35 during trading on Friday, reaching GBX 1,590. The stock had a trading volume of 275,001 shares, compared to its average volume of 4,574,925. The stock has a market cap of £3.29 billion, a P/E ratio of 9.03, a PEG ratio of 2.38 and a beta of 0.66. The business has a fifty day moving average price of GBX 1,602.32 and a 200-day moving average price of GBX 1,475.50. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,187 and a fifty-two week high of GBX 1,865. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57.

Insider Buying and Selling

In other news, insider Tobias Hestler acquired 7,500 shares of the stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of GBX 1,648 per share, for a total transaction of £123,600. 22.26% of the stock is currently owned by company insiders.

Hikma Pharmaceuticals News Summary

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Jefferies reaffirmed its “buy” rating and set a GBX 2,025 price target, implying meaningful upside from recent trading levels. The recommendation reinforces confidence in Hikma’s outlook and is likely supporting investor sentiment. Jefferies reaffirms buy rating and price target
• Positive Sentiment: Rebecca Hall has been appointed chief financial officer and executive director. Hall joins from ViiV Healthcare, where she was a senior finance leader. Her appointment may be viewed positively because of her pharmaceutical-sector experience and could strengthen Hikma’s financial and strategic execution. Hikma appoints Rebecca Hall as CFO
• Neutral Sentiment: Current CFO Khalid Nabilsi is stepping down as Hall becomes his successor. The transition is a notable governance and management change, but the available reports do not indicate operational disruption or a change to Hikma’s financial guidance. Hikma CFO transition

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.